Go to content
UR Home

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

Fritsch, K, Kasenda, B, Schorb, E, Hau, P, Bloehdorn, J, Möhle, R, Löw, S, Binder, M, Atta, J, Keller, U, Wolf, H-H, Krause, S W , Heß, G, Naumann, R, Sasse, S, Hirt, C, Lamprecht, M, Martens, U, Morgner, A, Panse, J, Frickhofen, N, Röth, A, Hader, C, Deckert, M, Fricker, H, Ihorst, G, Finke, J and Illerhaus, G (2017) High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 31 (4), pp. 846-852.

Full text not available from this repository.

at publisher (via DOI)

Other URL: http://doi.org/10.1038/leu.2016.334


Abstract

To investigate immuno-chemotherapy for elderly immuno-competent patients (. 65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m(2), days 1, 15, 29), high-dose methotrexate (3 g/m(2) days 2, 16, 30), procarbazine (60 mg/m(2) days 2-11) and lomustine (110 mg/m(2), day 2)-R-MPL protocol. Owing ...

plus


Export bibliographical data



Item type:Article
Date:2017
Institutions:Medicine > Lehrstuhl für Neurologie
Identification Number:
ValueType
10.1038/leu.2016.334DOI
Keywords:NERVOUS-SYSTEM LYMPHOMA; PHASE-II; EUROPEAN-ORGANIZATION; CLINICAL-TRIALS; PROCARBAZINE; RITUXIMAB; RADIOTHERAPY; TEMOZOLOMIDE; POPULATION; CYTARABINE;
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Status:Published
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Yes
Item ID:38570
Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons